Chapter
ADDITIONAL TAMOXIFEN BREAST CANCER PREVENTION TRIALS
THE STUDY OF TAMOXIFEN AND RALOXIFENE TRIAL, NSABP P-2
2009 AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINES ON THE USE OF PHARMACOLOGIC INTERVENTION, INCLUDING TAMOXIFEN, RALOXIFENE, AND AIS, FOR BREAST CANCER RISK REDUCTION
Chapter 2. Magnetic Resonance Imaging for Screening, Diagnosis, and Eligibility for Breast-conserving Surgery: Promises and Pitfalls
MRI FOR TREATMENT SELECTION
MRI FOR DETECTION OF LOCAL RECURRENCE
Chapter 3. Clinical Significance of Minimal Sentinel Node Involvement and Management Options
WHAT CONSTITUTES A POSITIVE SENTINEL LYMPH NODE?
TREATMENT OF SENTINEL NODE POSITIVE DISEASE: THE NEED FOR ALND?
Chapter 4. Clinical Significance and Management of Extra-Axillary Sentinel Lymph Nodes: Worthwhile or Irrelevant?
OTHER SITES OF NONAXILLARY SLN
Chapter 5. Sentinel Lymph Node Biopsy Before or After Neoadjuvant Chemotherapy: Pros and Cons
POTENTIAL ADVANTAGES TO SLN BIOPSY BEFORE NEOADJUVANT CHEMOTHERAPY
POTENTIAL ADVANTAGES TO SLN BIOPSY AFTER NEOADJUVANT CHEMOTHERAPY
MUST A POSITIVE PRETREATMENT SLN BIOPSY COMMIT A PATIENT TO AN ALND AFTER CHEMOTHERAPY?
IS SLN BIOPSY ACCURATE AFTER NEOADJUVANT CHEMOTHERAPY?
ACCURACY IN THE FACE OF CLINICALLY INVOLVED NODES BEFORE CHEMOTHERAPY
ACCURACY IN THE FACE OF CLINICALLY NEGATIVE NODES
IS IT SAFE TO AVOID ALND AFTER A NEGATIVE SLN BIOPSY FOLLOWING NEOADJUVANT CHEMOTHERAPY?
WHICH APPROACH PROVIDES THE MOST RELEVANT PROGNOSTIC/PREDICTIVE INFORMATION?
MUST ONE APPROACH BE UNIVERSALLY APPLIED?
Chapter 6. Sentinel Lymph Node Surgery in Uncommon Clinical Circumstances
PREGNANT PATIENTS WITH BREAST CANCER
MULTICENTRIC/MULTIFOCAL BREAST CANCER
PREVIOUS AXILLARY SURGERY
INTERNAL MAMMARY SLN SURGERY
Chapter 7. Total Skin Sparing (Nipple Sparing) Mastectomy: What is the Evidence?
PATIENT SELECTION FOR TOTAL SKIN SPARING MASTECTOMY
TECHNICAL APPROACHES: INCISION PLANNING
TECHNICAL CONSIDERATIONS: CREATING SKIN FLAPS
Chapter 8. Oncoplastic Surgery: A Creative Approach to Breast Cancer Management
DEFINITION OF ONCOPLASTIC SURGERY
ONCOPLASTIC SURGERY AND BREAST CANCER
Chapter 9. Clinical Application of Gene Expression Profiling in Breast Cancer
PROGNOSTIC AND PREDICTIVE MARKERS
PROCESS FOR DEVELOPMENT OF A MULTIPARAMETER ASSAY
METHODS FOR ANALYZING GENE EXPRESSION
QUALITY CONTROL OF GENE EXPRESSION ANALYSIS METHODS
METHODS FOR BIOINFORMATICS ANALYSIS OF GENE EXPRESSION
VALIDITY, REPRODUCIBILITY, AND REPORTING OF MICROARRAY STUDIES
REGULATORY APPROVAL OF MULTIPARAMETER ASSAYS
CLASSIFIERS DEVELOPED BY SUPERVISED ANALYSIS
MULTIPARAMETER ASSAYS COMPARED WITH INTEGRATED CLINICAL INFORMATION
CLASSIFIERS DEVELOPED BY OTHER METHODS
PROSPECTIVE CLINICAL TRIALS EVALUATING MULTIPARAMETER ASSAYS
CLINICAL USEFULNESS OF MULTIPARAMETER ASSAYS AND CONCLUSIONS
Chapter 10. Neoadjuvant Chemotherapy for Operable Breast Cancer: Individualizing Locoregional and Systemic Therapy
POTENTIAL BENEFITS OF NEOADJUVANT CHEMOTHERAPY FOR BREAST CANCER
PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY
CHEMOTHERAPY VERSUS HORMONAL THERAPY
PRE-THERAPY ASSESSMENT AND STAGING
OPTIMAL CHEMOTHERAPY REGIMEN
ASSESSING RESPONSE TO NEOADJUVANT CHEMOTHERAPY
RESECTION OF THE PRIMARY TUMOR: BREAST CONSERVATION VERSUS MASTECTOMY
MANAGEMENT OF REGIONAL LYMPH NODES IN PATIENTS TREATED WITH NCT
POSTMASTECTOMY REGIONAL/CHEST WALL IRRADIATION AFTER NEOADJUVANT CHEMOTHERAPY
Chapter 11. Neoadjuvant Endocrine Therapy for Breast Cancer
NEOADJUVANT CHEMOTHERAPY VERSUS ENDOCRINE THERAPY
BIOMARKER EVALUATION IN THE NEOADJUVANT ENDOCRINE SETTING TO PREDICT LONG-TERM OUTCOME
RECEPTOR, HER2 STATUS AND SENSITIVITY TO ENDOCRINE THERAPY
PATIENT SELECTION FOR NEOADJUVANT CHEMOTHERAPY
NEW COMBINATIONS WITH ENDOCRINE THERAPY IN THE NEOADJUVANT SETTING
Chapter 12. Adjuvant Hormonal Therapy for Early-Stage Breast Cancer
ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR–POSITIVE EARLY-STAGE BREAST CANCER
ADJUVANT ENDOCRINE THERAPY FOR PREMENOPAUSAL WOMEN WITH HORMONE RECEPTOR–POSITIVE EARLY-STAGE BREAST CANCER
Chapter 13. Adjuvant Chemotherapy in Early-Stage Breast Cancer: What, When, and for Whom?
WHO SHOULD BE CONSIDERED FOR ADJUVANT CHEMOTHERAPY?
WHAT ADJUVANT CHEMOTHERAPY?
TUMOR BIOLOGY AND CHOICE OF ADJUVANT CHEMOTHERAPY
ADJUVANT CHEMOTHERAPY WHEN?
Chapter 14. Targeted Therapies in Early-Stage Breast Cancer: Achievements and Promises
WHAT IS MEANT BY TARGETED THERAPY?
TARGETED THERAPY IN THE CONTEXT OF GENOMICS
NOVEL APPROACHES: ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
NOVEL APPROACHES: CHEMOTHERAPY AS TARGETED THERAPY
NOVEL APPROACHES: PARP INHIBITION FOR TRIPLE-NEGATIVE (BASAL) BREAST CANCER
NOVEL APPROACHES: TARGETING SITE-SPECIFIC BONE METASTASIS
Early-Stage Breast Cancer: New Developments and Controversies, An Issue of Surgical Oncology Clinics - E- Book
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
